|
1
|
Petersen I and Warth A: Lung cancer:
developments, concepts, and specific aspects of the new WHO
classification. J Cancer Res Clin Oncol. Jul 22–2015.(Epub ahead of
print).
|
|
2
|
Sobin L and Wittekind C: TNM
Classification of Malignant Tumours. 6th. John Wiley & Sons;
Hoboken, NJ: 2002
|
|
3
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Canadian Cancer Statistics 2010. Canadian
Cancer Society; Toronto: 2010
|
|
5
|
Morgensztern D, Ng SH, Gao F and Govindan
R: Trends in stage distribution for patients with non-small cell
lung cancer: a National Cancer Database survey. J Thorac Oncol.
5:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
World Health Organization, . WHO
definition of palliative care. http://www.who.int/cancer/palliative/definition/en/2010
|
|
7
|
Non-Small Cell Lung Cancer Collaborative
Group, . Chemotherapy and supportive care versus supportive care
alone for advanced non-small cell lung cancer. Cochrane Database
Syst Rev. 5:CD0073092010.PubMed/NCBI
|
|
8
|
Plunkett TA, Chrystal KF and Harper PG:
Quality of life and the treatment of advanced lung cancer. Clin
Lung Cancer. 5:28–32. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goffin J, Lacchetti C, Ellis PM, Ung YC
and Evans WK: Lung Cancer Disease Site Group of Cancer Care
Ontario's Program in Evidence-Based Care: First-line systemic
chemotherapy in the treatment of advanced non-small cell lung
cancer: a systematic review. J Thorac Oncol. 5:260–274. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okawara G, Mackay JA, Evans WK and Ung YC:
Lung Cancer Disease Site Group: A Clinical Practice
GuidelineManagement of Unresected Stage Ill Non-Small Cell Lung
Cancer. A Quality Initiative of the Program in Evidence-based Care
(PEBC), Cancer Care Ontario (CCO). Cancer Care Ontario; Toronto:
2006
|
|
11
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 13:(Suppl 1). 5–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Le Chevalier T, Scagliotti G, Natale R,
Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J,
Thatcher N, et al: Efficacy of gemcitabine plus platinum
chemotherapy compared with other platinum containing regimens in
advanced non-small-cell lung cancer: a meta-analysis of survival
outcomes. Lung Cancer. 47:69–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Addition of platinum compounds to a new
agent in patients with advanced non-small-cell lung cancer: a
literature based meta- analysis of randomised trials. Ann Oncol.
15:1782–1789. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing cisplatin to carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baggstrom MQ, Stinchcombe TE, Fried DB,
Poole C, Hensing TA and Socinski MA: Third-generation chemotherapy
agents in the treatment of advanced non-small cell lung cancer: a
meta-analysis. J Thorac Oncol. 2:845–853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Azzoli CG, Baker S Jr, Temin S, Pao W,
Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et
al: American Society of Clinical Oncology: American Society of
Clinical Oncology Clinical Practice Guideline update on
chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol.
27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Temel J: Complexities of quality of life
analysis in non-small cell lung cancer. J Support Oncol. 5:30–31.
2007.PubMed/NCBI
|
|
18
|
Silvestri G, Pritchard R and Welch HG:
Preferences for chemotherapy in patients with advanced non-small
cell lung cancer: descriptive study based on scripted interviews.
BMJ. 317:771–775. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stinnett S, Williams L and Johnson DH:
Role of chemotherapy for palliation in the lung cancer patient. J
Support Oncol. 5:19–24. 2007.PubMed/NCBI
|
|
20
|
Roszkowski K, Pluzanska A, Krzakowski M,
Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R and
Berille J: A multicenter, randomized, phase III study of docetaxel
plus best supportive care versus best supportive care in
chemotherapy-naive patients with metastatic or non-resectable
localized non-small cell lung cancer (NSCLC). Lung Cancer.
27:145–157. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brown J, Thorpe H, Napp V, Fairlamb DJ,
Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, et
al: Assessment of quality of life in the supportive care setting of
the big lung trial in non-small-cell lung cancer. J Clin Oncol.
23:7417–7427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanvetyanon T, Soares HP, Djulbegovic B,
Jacobsen PB and Bepler G: A systematic review of quality of life
associated with standard chemotherapy regimens for advanced
non-small cell lung cancer. J Thorac Oncol. 2:1091–1097. 2007.
View Article : Google Scholar : PubMed/NCBI
|
